

A Rare Case of Pulmonary Arterial Hypertension as the Initial Presentation of Systemic Lupus Erythematosus in a Pediatric Patient

Abstract: Pulmonary hypertension (PH) diagnosis can be challenging, particularly in young patients with systemic lupus erythematosus (SLE). We report a 10-year-old female presenting with suspected sinus venosus atrial septal defect (ASD) with Eisenmengerisation, later diagnosed with primary pulmonary arterial hypertension (PAH) secondary to SLE. She received vasodilators and immunosuppressants, showing partial treatment response.

Keywords: sinus venosus, pulmonary hypertension, antibodies, atrial septal defect, SLE

Introduction: Pulmonary hypertension (PH) poses diagnostic challenges in pediatric patients, often linked to structural cardiac abnormalities leading to Eisenmenger syndrome. SLE is a chronic autoimmune disease with diverse pulmonary manifestations, including PH, a rare and life-threatening complication. In Patients of SLE occurrence of pulmonary complications doesn't correspond to the duration of the disease (1). The usual prevalence of PAH in patient of SLE is 2.8 to 23.3 % (6). Pulmonary arterial hypertension (PAH) is a rare and a life-threatening complication and its diagnosis is usually delayed to due rarity and more than 40 percent patients with early PAH remains asymptomatic (2,7-10).

Here we describe a rare case of a young female who presented as a case of suspected sinus venosus atrial septal defect (ASD) with Eisenmengerisation and on thorough investigations was found to be suffering from PH secondary to SLE.

Case Presentation: A 10-year-old female presented with progressive exertional dyspnea (NYHA II-III) over three years. No signs or symptoms suggestive of SLE.

Initial evaluation revealed:

- Pulse: 96/min; BP: 90/60 mmHg; Respiratory rate: 24/min
- No pallor, icterus, clubbing, lymphadenopathy, or edema
- Cardiovascular examination: Loud P2, early diastolic murmur of grade III in pulmonary area and grade III parasternal heave.
- Other systemic examination: Normal.

Diagnostic Workup:

- Routine blood and urine tests: Normal.
- Thyroid function, renal function and hepatic function tests were within normal limits.
- Chest radiograph: Cardiomegaly and bilateral hilar prominence.
- Antinuclear antibody profile was strongly positive for PCNA antibody (1:320 titre).
- Electrocardiogram (ECG): Sinus tachycardia, P pulmonale, right ventricular hypertrophy with strain and right axis deviation.

- Echocardiography: Dilated right atrium and ventricle with severe pulmonary hypertension. Interatrial septum drop out of 2.5 mm was noted. Bubble contrast was suggestive of right to left shunt through PFO.
- Transesophageal echocardiography: Could not be done as the patient was uncooperative.
- Cardiac catheterization: MVO2 52.4%, Qp/Qs 0.6, PVR 34.26 WU.
- Cardiac CT done to rule out sinus venosus ASD was suggestive of an oblique slit like defect between the septum primum and septum secundum of 2 mm in mid portion of interatrial septum without any obvious jet suggestive of patent foramen ovale. Also, cardiomegaly with dilated right atrium (6.0 X 5.2 cm) and right ventricle (4.9 cm in mid ventricle level in diastole) with reflux of contrast in hepatic veins.
- CT pulmonary angiography was done to rule out any pulmonary AV malformations and AV fistulas and any extracardiac shunts and it was suggestive of dilated main pulmonary artery, left and right branch of pulmonary artery with P/A ratio of > 1 suggestive of PAH.
- Ultrasound of the abdomen and hepatoportal doppler done to look for intrahepatic shunts was within normal limits.
- CECT abdomen and pelvis done to look for any portosystemic shunt revealed normal study.

Discussion: SLE is an autoimmune disease characterized by spectrum of abnormalities (1). Occurrence of PAH in SLE is not uncommon but the occurrence of PAH in patients of SLE in younger age group is a rare entity (1, 3, 6). According to French registry mean age of PAH is 52 ± 15 years, with 25% of patients with > 60 years (2, 6). In majority of children PAH is associated with structural cardiac abnormality leading to Eisenmenger syndrome (3). Clinically differentiating patients with PPH with Eisenmenger syndrome is difficult (3). There is no significant association between the duration of SLE and the occurrence of pulmonary complications (1). Proliferating cell nuclear antigen (PCNA) is an intranuclear protein and has a role in DNA repair and replication. Anti-PCNA antibodies are considered a rare but highly specific marker for SLE (4, 5, 6).

Our patient, a young female presented with increasing intensity of dyspnea on exertion which initially appeared to be of cardiac origin (Pretricuspid shunt with Eisenmengerisation) from the history, physical examination and echocardiography. But further evaluation revealed primary PH due to SLE.

Conclusion: Differentiating PH from primary PAH in young patients can be challenging, leading to delayed diagnosis and treatment. A high index of suspicion is required as PAH can manifest without typical SLE symptoms. A Multidisciplinary approach with collaboration between rheumatologists, cardiologists, and pulmonologists ensures comprehensive care. Despite the rarity of PAH in young SLE patients, early diagnosis and treatment significantly improve outcomes. Comprehensive workup is essential to facilitate timely intervention and prevent disease progression.

Ethical Approval:

As per international standards or university standards written ethical approval has been collected and preserved by the author(s).

Consent

As per international standards, parental written consent has been collected and preserved by the author(s).

Disclaimer (Artificial intelligence)

Option 1:

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

Option 2:

Author(s) hereby declare that generative AI technologies such as Large Language Models, etc. have been used during the writing or editing of manuscripts. This explanation will include the name, version, model, and source of the generative AI technology and as well as all input prompts provided to the generative AI technology

Details of the AI usage are given below:

- 1.
- 2.
- 3.

References

1. Memet B, Ginzler EM. Pulmonary manifestations of systemic lupus erythematosus. *Semin Respir Crit Care Med.* 2007 Aug;28(4):441-50. doi: 10.1055/s-2007-985665. PMID: 17764061.
2. Memon HA, Park MH. Pulmonary Arterial Hypertension in Women. *Methodist DeBakey Cardiovasc J.* 2017 Oct-Dec;13(4):224-237. doi: 10.14797/mdcj-13-4-224. PMID: 29744015; PMCID: PMC5935282.
3. Haworth SG. Pulmonary hypertension in the young. *Heart.* 2002 Dec;88(6):658-64. doi:10.1136/heart.88.6.658. PMID: 12433912; PMCID: PMC1767475.
4. Vermeersch P, De Beeck KO, Lauwerys BR, et al Antinuclear antibodies directed against proliferating cell nuclear antigen are not specifically associated with systemic lupus erythematosus *Annals of the Rheumatic Diseases* 2009;68:1791-1793.
5. Satoh M, Vázquez-Del Mercado M, Chan EK. Clinical interpretation of antinuclear antibody tests in systemic rheumatic diseases. *Mod Rheumatol.* 2009;19(3):219-28. doi: 10.1007/s10165-009-0155-3. Epub 2009 Mar 10. PMID: 19277826; PMCID: PMC2876095.

6. Xia YK, Tu SH, Hu YH, Wang Y, Chen Z, Day HT, Ross K. Pulmonary hypertension in systemic lupus erythematosus: a systematic review and analysis of 642 cases in Chinese population. *Rheumatol Int.* 2013 May;33(5):1211-7. doi: 10.1007/s00296-012-2525-y. Epub 2012 Sep 16. PMID: 22983159; PMCID: PMC3632720.
7. Anuardo P, Verdier M, Gormezano NW, Ferreira GR, Leal GN, Lianza A, Ferreira JC, Pereira RM, Aikawa NE, Terreri MT, Magalhaes CS. Subclinical pulmonary hypertension in childhood systemic lupus erythematosus associated with minor disease manifestations. *Pediatric cardiology.* 2017 Feb;38:234-9.
8. Hachulla E, Jais X, Cinquetti G, Clerson P, Rottat L, Launay D, Cottin V, Habib G, Prevot G, Chabanne C, Foïs E. Pulmonary arterial hypertension associated with systemic lupus erythematosus: results from the French Pulmonary Hypertension Registry. *Chest.* 2018 Jan 1;153(1):143-51.
9. Tselios K, Urowitz MB. Cardiovascular and pulmonary manifestations of systemic lupus erythematosus. *Current rheumatology reviews.* 2017 Dec 1;13(3):206-18.
10. Kamel SR, Omar GM, Darwish AF, Asklany HT, Ellabban AS. Asymptomatic pulmonary hypertension in systemic lupus erythematosus. *Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders.* 2011 Jan;4:CMAMD-S7667.